Granules India Valuation
Is 532482 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 532482 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 532482 (₹437.8) wird unter unserer Schätzung des Fair Value (₹1832.38) gehandelt.
Deutlich unter dem Marktwert: 532482 wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 532482?
Other financial metrics that can be useful for relative valuation.
| What is 532482's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₹109.72b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | 14.5x |
| PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does 532482's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 59.1x | ||
AETHER Aether Industries | 92.1x | 40.5% | ₹112.7b |
524742 Caplin Point Laboratories | 22.2x | 11.0% | ₹97.3b |
ERIS Eris Lifesciences | 30x | 15.9% | ₹115.8b |
506820 AstraZeneca Pharma India | 92.2x | n/a | ₹128.5b |
532482 Granules India | 27.8x | 25.1% | ₹109.7b |
Price-To-Earnings gegen Gleichaltrige: 532482 ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (23.7x) mit dem Durchschnitt der anderen Unternehmen (28.6x) vergleicht.
Price to Earnings Ratio vs Industry
How does 532482's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 532482 ist aufgrund seines Price-To-Earnings Verhältnisses (28x) im Vergleich zum Indian Pharmaceuticals Branchendurchschnitt (34.9x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 532482's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 27.8x |
| Fair PE Ratio | 34.9x |
PM vs. Fair Ratio: 532482 ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (28x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (36.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹452.70 | ₹478.43 +5.7% | 4.3% | ₹515.00 | ₹455.00 | n/a | 7 |
| Mar ’25 | ₹463.85 | ₹472.33 +1.8% | 3.2% | ₹500.00 | ₹455.00 | n/a | 6 |
| Feb ’25 | ₹411.85 | ₹472.33 +14.7% | 3.2% | ₹500.00 | ₹455.00 | n/a | 6 |
| Jan ’25 | ₹411.65 | ₹404.00 -1.9% | 11.3% | ₹464.00 | ₹320.00 | n/a | 7 |
| Dec ’24 | ₹392.70 | ₹391.38 -0.3% | 13.8% | ₹464.00 | ₹303.00 | n/a | 8 |
| Nov ’24 | ₹337.40 | ₹356.71 +5.7% | 14.4% | ₹437.00 | ₹277.00 | n/a | 7 |
| Oct ’24 | ₹354.75 | ₹341.14 -3.8% | 9.9% | ₹370.00 | ₹277.00 | n/a | 7 |
| Sep ’24 | ₹302.30 | ₹341.14 +12.8% | 9.9% | ₹370.00 | ₹277.00 | n/a | 7 |
| Aug ’24 | ₹326.20 | ₹358.29 +9.8% | 12.1% | ₹452.00 | ₹303.00 | n/a | 7 |
| Jul ’24 | ₹296.95 | ₹359.67 +21.1% | 13.0% | ₹452.00 | ₹303.00 | n/a | 6 |
| Jun ’24 | ₹287.90 | ₹358.83 +24.6% | 13.0% | ₹452.00 | ₹303.00 | n/a | 6 |
| May ’24 | ₹300.15 | ₹378.17 +26.0% | 9.4% | ₹452.00 | ₹345.00 | n/a | 6 |
| Apr ’24 | ₹290.75 | ₹378.17 +30.1% | 9.4% | ₹452.00 | ₹345.00 | ₹437.80 | 6 |
| Mar ’24 | ₹283.60 | ₹371.57 +31.0% | 9.9% | ₹452.00 | ₹332.00 | ₹463.85 | 7 |
| Feb ’24 | ₹291.30 | ₹371.57 +27.6% | 9.9% | ₹452.00 | ₹332.00 | ₹411.85 | 7 |
| Jan ’24 | ₹318.65 | ₹367.71 +15.4% | 6.5% | ₹410.00 | ₹332.00 | ₹411.65 | 7 |
| Dec ’23 | ₹340.75 | ₹367.38 +7.8% | 6.1% | ₹410.00 | ₹332.00 | ₹392.70 | 8 |
| Nov ’23 | ₹373.55 | ₹367.38 -1.7% | 6.1% | ₹410.00 | ₹332.00 | ₹337.40 | 8 |
| Oct ’23 | ₹345.25 | ₹346.88 +0.5% | 5.5% | ₹375.00 | ₹320.00 | ₹354.75 | 8 |
| Sep ’23 | ₹305.85 | ₹346.88 +13.4% | 5.5% | ₹375.00 | ₹320.00 | ₹302.30 | 8 |
| Aug ’23 | ₹304.10 | ₹311.25 +2.4% | 10.4% | ₹365.00 | ₹270.00 | ₹326.20 | 8 |
| Jul ’23 | ₹278.50 | ₹307.50 +10.4% | 10.3% | ₹365.00 | ₹270.00 | ₹296.95 | 8 |
| Jun ’23 | ₹270.05 | ₹322.67 +19.5% | 12.0% | ₹385.00 | ₹270.00 | ₹287.90 | 9 |
| May ’23 | ₹281.10 | ₹353.00 +25.6% | 9.5% | ₹404.00 | ₹306.00 | ₹300.15 | 9 |
| Apr ’23 | ₹313.00 | ₹358.88 +14.7% | 8.6% | ₹404.00 | ₹315.00 | ₹290.75 | 8 |
Analysten-Prognose: Das Kursziel liegt weniger als 20% über dem aktuellen Aktienkurs.